Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in parkinson's disease

Sophie Virachit, Kathryn J. Mathews, Veronica Cottam, Eryn Werry, Emilia Galli, Elisabeth Rappou, Pӓivi Lindholm, Mart Saarma, Glenda M. Halliday, Cynthia Shannon Weickert, Kay L. Double

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Sammanfattning

Abstract Growth factors can facilitate hippocampus-based learning and memory and are potential targets for treatment of cognitive dysfunction via their neuroprotective and neurorestorative effects. Dementia is common in Parkinson's disease (PD), but treatment options are limited. We aimed to determine if levels of growth factors are altered in the hippocampus of patients with PD, and if such alterations are associated with PD pathology. Enzyme-linked immunoassays were used to quantify seven growth factors in fresh frozen hippocampus from ten PD and nine age-matched control brains. Western blotting and immunohistochemistry were used to explore cellular and inflammatory changes that may be associated with growth factor alterations. In the PD hippocampus, protein levels of the glial cell line-derived neurotrophic factor (GDNF) were significantly decreased, despite no evidence of neuronal loss. In contrast, protein levels of fibroblast growth factor 2 (FGF2) and cerebral dopamine neurotrophic factor (CDNF) were significantly increased in PD compared to controls. Levels of the growth factors epidermal growth factor (EGF), heparin binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) did not differ between groups. Our data demonstrate changes in specific growth factors in the hippocampus of the PD brain, which potentially represent targets for modification to help attenuate cognitive decline in PD. This data also suggests that multiple growth factors and direction of change needs to be considered when approaching growth factors as a potential treatment for cognitive decline. This article is protected by copyright. All rights reserved.
Originalspråkengelska
TidskriftBrain Pathology
ISSN1015-6305
DOI
Status!!E-pub ahead of print - 29 apr 2019
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3112 Neurovetenskaper

Citera det här

Virachit, Sophie ; Mathews, Kathryn J. ; Cottam, Veronica ; Werry, Eryn ; Galli, Emilia ; Rappou, Elisabeth ; Lindholm, Pӓivi ; Saarma, Mart ; Halliday, Glenda M. ; Shannon Weickert, Cynthia ; Double, Kay L. / Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in parkinson's disease. I: Brain Pathology. 2019.
@article{05966293eb3d4d01a353923599be0cbc,
title = "Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in parkinson's disease",
abstract = "Abstract Growth factors can facilitate hippocampus-based learning and memory and are potential targets for treatment of cognitive dysfunction via their neuroprotective and neurorestorative effects. Dementia is common in Parkinson's disease (PD), but treatment options are limited. We aimed to determine if levels of growth factors are altered in the hippocampus of patients with PD, and if such alterations are associated with PD pathology. Enzyme-linked immunoassays were used to quantify seven growth factors in fresh frozen hippocampus from ten PD and nine age-matched control brains. Western blotting and immunohistochemistry were used to explore cellular and inflammatory changes that may be associated with growth factor alterations. In the PD hippocampus, protein levels of the glial cell line-derived neurotrophic factor (GDNF) were significantly decreased, despite no evidence of neuronal loss. In contrast, protein levels of fibroblast growth factor 2 (FGF2) and cerebral dopamine neurotrophic factor (CDNF) were significantly increased in PD compared to controls. Levels of the growth factors epidermal growth factor (EGF), heparin binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) did not differ between groups. Our data demonstrate changes in specific growth factors in the hippocampus of the PD brain, which potentially represent targets for modification to help attenuate cognitive decline in PD. This data also suggests that multiple growth factors and direction of change needs to be considered when approaching growth factors as a potential treatment for cognitive decline. This article is protected by copyright. All rights reserved.",
keywords = "Parkinson's disease, hippocampus, fibroblast growth factor 2, glial cell line-derived neurotrophic factor, cerebral dopamine neurotrophic factor, 3112 Neurosciences",
author = "Sophie Virachit and Mathews, {Kathryn J.} and Veronica Cottam and Eryn Werry and Emilia Galli and Elisabeth Rappou and Pӓivi Lindholm and Mart Saarma and Halliday, {Glenda M.} and {Shannon Weickert}, Cynthia and Double, {Kay L.}",
year = "2019",
month = "4",
day = "29",
doi = "10.1111/bpa.12730",
language = "English",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "John Wiley & Sons, Ltd (10.1111)",

}

Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in parkinson's disease. / Virachit, Sophie; Mathews, Kathryn J.; Cottam, Veronica; Werry, Eryn; Galli, Emilia; Rappou, Elisabeth; Lindholm, Pӓivi; Saarma, Mart; Halliday, Glenda M.; Shannon Weickert, Cynthia; Double, Kay L.

I: Brain Pathology, 29.04.2019.

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

TY - JOUR

T1 - Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in parkinson's disease

AU - Virachit, Sophie

AU - Mathews, Kathryn J.

AU - Cottam, Veronica

AU - Werry, Eryn

AU - Galli, Emilia

AU - Rappou, Elisabeth

AU - Lindholm, Pӓivi

AU - Saarma, Mart

AU - Halliday, Glenda M.

AU - Shannon Weickert, Cynthia

AU - Double, Kay L.

PY - 2019/4/29

Y1 - 2019/4/29

N2 - Abstract Growth factors can facilitate hippocampus-based learning and memory and are potential targets for treatment of cognitive dysfunction via their neuroprotective and neurorestorative effects. Dementia is common in Parkinson's disease (PD), but treatment options are limited. We aimed to determine if levels of growth factors are altered in the hippocampus of patients with PD, and if such alterations are associated with PD pathology. Enzyme-linked immunoassays were used to quantify seven growth factors in fresh frozen hippocampus from ten PD and nine age-matched control brains. Western blotting and immunohistochemistry were used to explore cellular and inflammatory changes that may be associated with growth factor alterations. In the PD hippocampus, protein levels of the glial cell line-derived neurotrophic factor (GDNF) were significantly decreased, despite no evidence of neuronal loss. In contrast, protein levels of fibroblast growth factor 2 (FGF2) and cerebral dopamine neurotrophic factor (CDNF) were significantly increased in PD compared to controls. Levels of the growth factors epidermal growth factor (EGF), heparin binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) did not differ between groups. Our data demonstrate changes in specific growth factors in the hippocampus of the PD brain, which potentially represent targets for modification to help attenuate cognitive decline in PD. This data also suggests that multiple growth factors and direction of change needs to be considered when approaching growth factors as a potential treatment for cognitive decline. This article is protected by copyright. All rights reserved.

AB - Abstract Growth factors can facilitate hippocampus-based learning and memory and are potential targets for treatment of cognitive dysfunction via their neuroprotective and neurorestorative effects. Dementia is common in Parkinson's disease (PD), but treatment options are limited. We aimed to determine if levels of growth factors are altered in the hippocampus of patients with PD, and if such alterations are associated with PD pathology. Enzyme-linked immunoassays were used to quantify seven growth factors in fresh frozen hippocampus from ten PD and nine age-matched control brains. Western blotting and immunohistochemistry were used to explore cellular and inflammatory changes that may be associated with growth factor alterations. In the PD hippocampus, protein levels of the glial cell line-derived neurotrophic factor (GDNF) were significantly decreased, despite no evidence of neuronal loss. In contrast, protein levels of fibroblast growth factor 2 (FGF2) and cerebral dopamine neurotrophic factor (CDNF) were significantly increased in PD compared to controls. Levels of the growth factors epidermal growth factor (EGF), heparin binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) did not differ between groups. Our data demonstrate changes in specific growth factors in the hippocampus of the PD brain, which potentially represent targets for modification to help attenuate cognitive decline in PD. This data also suggests that multiple growth factors and direction of change needs to be considered when approaching growth factors as a potential treatment for cognitive decline. This article is protected by copyright. All rights reserved.

KW - Parkinson's disease

KW - hippocampus

KW - fibroblast growth factor 2

KW - glial cell line-derived neurotrophic factor

KW - cerebral dopamine neurotrophic factor

KW - 3112 Neurosciences

U2 - 10.1111/bpa.12730

DO - 10.1111/bpa.12730

M3 - Article

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

ER -